

Recce Raises A\$4.0 million via Institutional Placement and Announces Share Purchase Plan

Highlights:

- Recce has received firm commitments to raise A\$4.0 million via an institutional placement at A\$0.40 per share
- The placement was well supported by new and existing institutional, sophisticated and professional investors
- Proceeds will be used to strengthen the balance sheet for commercial licensing with a leading Middle Eastern pharmaceutical company, fund ongoing clinical trials, Investigational New Drug enabling activities and provide additional general working capital
- Share Purchase Plan (SPP) to be launched to provide eligible shareholders the opportunity to participate on the same terms as the Placement
- Attaching Options: Participants in both the Placement and SPP will receive one (1) free-attaching unlisted option for every two (2) New Shares issued
- Piggyback Options: Upon the valid exercise of each Attaching Option, holders will automatically receive two (2) unlisted piggyback options

Sydney Australia, 26 June 2026: Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**), (**Recce or the Company**), a leading developer of synthetic anti-infectives, is pleased to announce it has received firm commitments from sophisticated, professional, and institutional investors to raise A\$4.0 million (before costs) via a placement of 10.0 million new fully paid ordinary shares (**New Shares**) at an issue price of A\$0.40 per New Share (**Placement**).

The Company is also launching a Share Purchase Plan (**SPP**) to provide Eligible Shareholders an opportunity to subscribe for up to \$30,000 worth of new fully paid ordinary shares (**SPP Shares**) to raise up to an additional A\$4.0 million (before costs) on the same terms as the Placement. An Eligible Shareholder is a holder of fully paid ordinary shares in the Company as at 7.00pm (AEST) on Thursday, 25 June 2026 with a registered address in Australia, New Zealand or who are Accredited Investors in the United States and who are otherwise eligible to participate in the SPP under the terms of the SPP offer.



Commenting on the capital raising, Chief Executive Officer, James Graham said:

“We are delighted with the support of our capital raising from our existing shareholders and welcome new shareholders to our register. The capital raising comes at an exciting time for the Recce business, having recently signed a non-binding term sheet with a leading Middle Eastern Pharmaceuticals Company and ahead of interim data readouts in Indonesia which is a positive step towards the potential commercialisation of R327G.

The Company has many key milestones over the next 12 months and we look forward to keeping shareholders up to date on our progress. We acknowledge and appreciate the support of our retail shareholders. As a Board we are pleased to be able to offer the ability for shareholders to participate in the Company’s capital raising activities on the same terms as the Placement through the Share Purchase Plan.”

Use of Funds and Available Liquidity

Funds raised under the Placement and SPP (**Offer**) will be used for the following activities:

- A\$3.2 million – Strengthen the balance sheet for commercial licensing with leading Middle Eastern Pharmaceutical Company including initiatives to support the commercial agreement
- A\$2.0 million – Clinical trials (significant, unmet medical needs) including:
 - Completion of Phase 3 Diabetic Foot Infections (DFI) Registrational Topical Clinical Trial in Indonesia
 - Phase 3 DFI Registrational Topical Clinical Trial in Australia (for US FDA)
 - Continuance of US Department of War Burn Wound Program
- A\$2.0 million – Activities enabling Investigational New Drug application to FDA & the Indonesia FDA (BPOM)
- A\$0.8 million – General working capital (operational costs delivering above) and Offer costs;

Post the Offer, Recce expects to have pro forma cash liquidity (before Offer costs) of approximately A\$29.5 million. In addition, Recce anticipates additional funding through an estimated R&D Rebate (A\$7.5 million) and non-dilutive capital through R&D Advance (A\$10 million). With a possible further A\$10 million drawdown under the existing Avenue Capital debt facility, total cash runway reaches approximately A\$29.5 million.

Placement and SPP Details

Key details of the Placement and SPP are as follows:

- Offer price for New Shares and SPP Shares at A\$0.40 per share representing a:
 - 13.0% discount to the last closing price of \$0.46 on 23 June 2026;
 - 18.3% discount to the 5-day Volume Weighted Average Price (**VWAP**) of \$0.490 up to and including 23 June 2026 being the last trading day prior to the announcement of the Placement & SPP; and
 - 19.4% discount to the 10-day VWAP of \$0.497.
- Participants in the Placement and SPP will receive one (1) free unlisted attaching option (**Attaching Options**) for every two (2) New Shares and SPP Shares allocated with an exercise price of A\$0.60 per option expiring 30 June 2027. Fractional entitlements to Attaching Options will be rounded down to the nearest whole number.
- Holders of Attaching Options will receive one (1) fully paid ordinary share and two (2) free unlisted piggyback options (**Piggyback Options**) for every one (1) Attaching Option exercised.
- The Piggyback Options will have an exercise price of A\$1.00 and expire 30 June 2028. Each Piggyback Option gives the holder the right to receive one (1) fully paid ordinary share upon exercise.
- The offer of the Attaching Options and Piggyback Options will be made pursuant to a prospectus to facilitate secondary trading of shares issued upon exercise of the Attaching Options and Piggyback Options which is to be lodged with ASIC and the ASX in the coming weeks. The Attaching Options and Piggyback Options remain subject to formal confirmation from ASX that the structure and terms of the options comply with the Listing Rules.

Ord Minnett Limited acted as Lead Manager to the Offer with SP Corporate Advisory Pty Ltd acting as Co-Lead Manager.

Capacity Utilisation and EGM

The New Shares, Attaching Options and Piggyback Options proposed to be issued to participants in the Placement will be issued utilising the Company's placement capacity under ASX Listing Rule 7.1.

The SPP Shares will be issued under Listing Rule 7.2 (Exception 5). Listing Rule 7.2 (Exception 5) is not available to issue the Attaching Options and Piggyback Options (together the **SPP Options**) to SPP participants. Accordingly the SPP Options are subject to shareholder approval at an upcoming EGM. Furthermore, while participating Company Directors can receive SPP Shares under Listing Rule 10.12 (Exception 4), their allocation of SPP Options will also be subject to shareholder approval under Listing Rule 10.11 at the EGM.

General

Shares issued under the Placement and SPP will rank equally with existing fully paid ordinary shares of the Company from their issue date. Shares issued upon exercise of the Attaching Options and Piggyback Options will also rank equally with existing fully paid ordinary shares of the Company from their issue date.

The Company reserves the right to determine the aggregate amount it raises through the SPP. Recce may (in its absolute discretion) in a situation where total demand exceeds A\$4.0 million, decide to increase the amount to be raised under the SPP to reduce or eliminate the need for scale back; and/or undertake a scale back of applications to the extent and in the manner it sees fit. Funds raised from the SPP are intended to be used for the same purposes as those funds raised under the Placement.

Further details on the Placement and SPP are set out in the investor presentation released by Recce to ASX on 26 June 2026, as well as the SPP Offer Booklet which is expected to be made available on the ASX on or around Monday, 6 July 2026.

Those Eligible Shareholders who have not registered their email with the share registry and would like to receive a copy of the Offer Booklet electronically should contact Automic Group at:

Email: hello@automicgroup.com.au

Address: Level 5/126 Phillip St, Sydney NSW 2000

Phone: 1300 288 664 (within Australia), or +61 2 9698 5414 (international) between 8:30 am and 7:00 pm (AEST time) Monday to Friday.

The indicative timetable for the Placement and SPP is as follows:

Event	Date
SPP Record Date	7.00pm (Sydney time), Thursday, 25 June 2026
Announcement of Placement and SPP and trading	Friday, 26 June 2026

halt lifted	
Placement settlement	Tuesday, 30 June 2026
Allotment and commencement of trading of Placement shares	Wednesday, 1 July 2026
SPP Offer Documents made available to eligible shareholders and SPP offer open date	Monday, 6 July 2026
SPP offer closing date	5:00pm (Sydney time) Monday, 20 July 2026
Last day to announce results of SPP	Monday, 27 July 2026
Allotment and issue of new shares under the SPP	Monday, 27 July 2026
Commencement of trading of new shares under the SPP	Tuesday, 28 July 2026
Extraordinary General Meeting (EGM)	On or about Monday, 31 August 2026
Lodgement of Prospectus with ASIC and ASX in relation to Attaching Options and Piggyback Options	On or about Wednesday, 2 September 2026

The timetable above is indicative only and remains subject to change at Recce's discretion, subject to compliance with applicable laws and the ASX Listing Rules. Recce reserves the right to change the timetable or cancel or withdraw the SPP at any time before relevant new Shares are issued, subject to regulatory requirements.

Recce reserves the right to close the SPP early or to accept late applications, in its sole and absolute discretion, should it be considered necessary to do so, by making an announcement to ASX. The commencement and quotation of shares offered under the Placement or SPP is subject to confirmation from ASX. Recce also reserves the right to place any shortfall of the SPP to institutional or sophisticated investors at its absolute discretion.

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.